Docstoc

U.S. Vaccine Market is Expected to Reach USD 17.4 Billion by 2018: Transparency Market Research

Document Sample
U.S. Vaccine Market is Expected to Reach USD 17.4 Billion by 2018: Transparency Market Research Powered By Docstoc
					Transparency Market Research




U.S. Vaccine Market is                                                    Buy Now
Expected to Reach USD
                                                                          Request Sample
17.4 Billion by 2018:
Transparency Market                                                   Published Date: June 2013
Research

 Single User License: US $ 4595
                                                                                82 Pages Report
 Multi User License: US $ 7595

 Corporate User License: US $ 10595



     REPORT DESCRIPTION

     U.S. Vaccine Market - Industry Analysis, Size, Share, Growth, And Forecast 2012 -
     2018

     The U.S. vaccine market is estimated to be worth USD 12.8 billion in 2012 and is further
     expected to reach USD 17.4 billion by 2018, growing at a CAGR of 5.3% from 2012 to 2018.
     Human vaccine segment occupies about 80% of the U.S. vaccine market.

     U.S. will continue to lead the global vaccine market due to rising prevalence of infectious
     diseases in humans and animals, and advancement in biotechnology in the region. Short
     functional shelf life of certain vaccines will have negative impact on the market growth, but
     huge product pipeline of the multinational firms will overcome this concern and will drive the
     future growth of the market.

     Pediatric vaccine segment in the U.S. human vaccine market enjoys high share as well as
     high growth rate due to government compulsion for child immunization. Adult & adolescent
     vaccine market is expected to grow moderately over the next six years due to rising
     awareness and increasing vaccination for human papillomavirus (HPV) and such other viral
     diseases.
Browse Report : U.S. human vaccine market

Livestock vaccine is the leading segment of the overall U.S. animal vaccine market
accounting for 58.1% in 2012 due to more organized dairy sector and increased awareness
towards prevention of infectious diseases in cattle. Bovine vaccine market is the largest
revenue generating segment of the overall Livestock vaccine market in 2012 due to rising
vaccination to protect breeding animals against infectious diseases. Together feline vaccine
and canine vaccine accounted for about 95.1% of the overall U.S. companion animal vaccine
market in 2011.

In 2011, overall leading producers of human vaccine for the U.S. market were Sanofi-
Aventis, Merck, GlaxoSmithKline, Pfizer, Sanofi-Pasture and Novartis. The leading producers
of animal vaccine for the U.S. market includes Pfizer Animal Health, Merial (Sanofi-Aventis),
Intervet/Schering-Plough (Merck) and Novartis Animal Health.

This report helps to identify factors, which will be the driving force behind the U.S. Vaccine
market and sub-markets in the next six years. The report provides extensive analysis of the
U.S. vaccine market, current market trends, industry drivers and challenges for better
understanding of the U.S. vaccine market structure. The report has segregated the U.S.
vaccine industry in terms of its product type. Annual estimates and forecasts are provided
for the period 2012 through 2018 in terms of value in USD million.

Segments Analyzed

U.S. vaccine market- by Product

      Human vaccine

             Pediatric Vaccines

             Adult & Adolescent vaccine

             Other human vaccine

      Animal vaccine

             Livestock vaccine

                     Bovine vaccine

                     Porcine vaccine

                     Ovine vaccine

             Companion animal vaccine

                     Feline vaccine

                     Canine vaccine

                     Equine vaccine
              Other animal vaccine

Browse the database at http://www.transparencymarketresearch.com/us-
vaccine-market.html



TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION

1.1 REPORT DESCRIPTION

1.2 METHODOLOGY



CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 U.S. VACCINE MARKET, 2012 - 2018

3.1 MARKET OVERVIEW

3.2 VACCINE MARKET CHARACTERISTICS

3.3 LAWS AND REGULATIONS

3.3.1 VACCINE APPROVAL PROCESS

3.4 U.S. VACCINE MARKET ESTIMATE AND FORECAST, 2012 - 2018

3.4.1 MARKET SHARE BY VACCINE TYPE

3.5 LIST OF COMPANIES SUPPLYING VACCINES IN THE U.S.

3.6 VACCINE PRICING

3.6.1 PRICES FOR VACCINES CONTAINING THIMEROSAL AS A PRESERVATIVE

3.6.2 PRICES OF VACCINES FREE OF PRESERVATIVES:

3.7 MARKET DYNAMICS

    3.7.1 DRIVERS

           3.7.1.1 Rise in incidences of viral infection driving the growth of vaccine market in
the U.S.

         3.7.1.2 Biotechnology research enabling synthesis of new vaccines to target
complex human diseases driving the vaccine market

          3.7.1.3 Government recommendation for adult and adolescent immunization will
boost the growth of Vaccine market in U.S.
          3.7.1.4 Rise in infectious diseases in animals driving the market

    3.7.2 RESTRAINTS

          3.7.2.1 Cost of refrigeration

         3.7.2.2 Short functional shelf life of certain vaccines will have negative impact on
the market growth

   3.7.3 OPPORTUNITIES

          3.7.3.1 Huge product pipeline of the multinational firms will act as an opportunity
for future growth

3.8 IMPACT ANALYSIS OF DRIVERS

3.9 IMPACT ANALYSIS OF RESTRAINTS

3.10 PORTER’S FIVE FORCE ANALYSIS

     3.10.1 BARGAINING POWER OF SUPPLIER

     3.10.2 BARGAINING POWER OF BUYER

     3.10.3 RIVALRY AMONG EXISTING COMPETITORS

     3.10.4 THREAT OF NEW ENTRANTS

     3.10.5 THREAT OF SUBSTITUTE



CHAPTER 4 U.S. VACCINE MARKET BY PRODUCT TYPE

4.1 HUMAN VACCINE

     4.1.1 MARKET ANALYSIS, SIZE AND FORECAST

     4.1.2 MARKET ATTRACTIVENESS ANALYSIS FOR HUMAN VACCINE MARKET

     4.1.3 PEDIATRIC VACCINES

          4.1.3.1 Market Analysis, Size and Forecast

          4.1.3.2 Pediatric vaccine price list

          4.1.3.3 Pediatric Influenza Vaccine price list

          4.1.3.4 HaemophilusInfluenzae Type B

                  4.1.3.4.1 Hib Pricing

          4.1.3.5 Hepatitis A
Browse the database at http://www.transparencymarketresearch.com/us-
vaccine-market.html



                4.1.3.5.1 HAV Pricing

        4.1.3.6 Hepatitis B

                4.1.3.6.1 Hepatitis B Pricing

   4.1.4 ADULT & ADOLESCENT VACCINES

        4.1.4.1 Market Analysis, Size and Forecast

        4.1.4.2 Adult vaccine price list

        4.1.4.3 Adult Influenza Vaccine price list

   4.1.5 OTHER HUMAN VACCINES

        4.1.5.1 Market Analysis, Size and Forecast

4.2 ANIMAL VACCINE

   4.2.1 MARKET ANALYSIS, SIZE AND FORECAST

   4.2.2 MARKET ATTRACTIVENESS ANALYSIS FOR ANIMAL VACCINE

   4.2.3 LIVESTOCK VACCINES

        4.2.3.1 Market Analysis, Size and Forecast

        4.2.3.2 Bovine Vaccines

               4.2.3.2.1 Market Analysis, Size and Forecast

        4.2.3.3 Porcine Vaccines

               4.2.3.3.1 Market Analysis, Size and Forecast

        4.2.3.4 Ovine Vaccines

               4.2.3.4.1 Market Analysis, Size and Forecast

  4.2.4 COMPANION ANIMAL VACCINES

        4.2.4.1 Market Analysis, Size and Forecast

        4.2.4.2 Feline Vaccines

               4.2.4.2.1 Market Analysis, Size and Forecast
        4.2.4.3 Canine Vaccines

               4.2.4.3.1 Market Analysis, Size and Forecast

        4.2.4.4 Equine Vaccines

               4.2.4.4.1 Market Analysis, Size and Forecast

   4.2.5 OTHER ANIMAL VACCINES

        4.2.5.1 Market Analysis, Size and Forecast



CHAPTER 5 COMPETITIVE LANDSCAPE

5.1 MARKET SHARE ANALYSIS

5.2 COMPETITIVE ANALYSIS FOR KEY MARKET PLAYERS



CHAPTER 6 COMPANY PROFILE

6.1 SANOFI-AVENTIS

   6.1.1 COMPANY OVERVIEW

   6.1.2 FINANCIAL OVERVIEW

   6.1.3 SWOT ANALYSIS

   6.1.1 RECENT DEVELOPMENT

6.2 GLAXOSMITHKLINE

   6.2.1 COMPANY OVERVIEW

   6.2.2 FINANCIAL OVERVIEW:

   6.2.3 SEGMENT OVERVIEW

   6.2.4 SWOT ANALYSIS

   6.2.5 RECENT DEVELOPMENTS

6.3 MERCK & COMPANY INCORPORATED

   6.3.1 COMPANY OVERVIEW

   6.3.2 FINANCIAL OVERVIEW:

   6.3.1 RECENT DEVELOPMENT
Browse the database at http://www.transparencymarketresearch.com/us-
vaccine-market.html



6.4 PFIZER INCORPORATED

    6.4.1 COMPANY OVERVIEW

    6.4.2 FINANCIAL OVERVIEW

    6.4.3 RECENT DEVELOPMENT

6.5 ASTRAZENECA PLC

    6.5.1 COMPANY OVERVIEW

    6.5.2 FINANCIAL OVERVIEW:

    6.5.3 RECENT DEVELOPMENT

6.6 NOVARTIS AG

    6.6.1 COMPANY OVERVIEW

    6.6.2 FINANCIAL OVERVIEW:

    6.6.3 SWOT ANALYSIS

    6.6.1 RECENT DEVELOPMENT

6.7 BOEHRINGER

    6.7.1 COMPANY OVERVIEW

    6.7.2 NET SALES BY BUSINESS

    6.7.3 SWOT ANALYSIS

    6.7.4 RECENT DEVELOPMENT



About Us:

Transparency Market Research is a market intelligence company providing global business
information reports and services. Our exclusive blend of quantitative forecasting and trends
analysis provides forward-looking insight for thousands of decision makers.

We are privileged with highly experienced team of Analysts, Researchers and Consultants,
who use proprietary data sources and various tools and techniques to gather, and analyze
information. Our business offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.


Contact:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States

Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

				
DOCUMENT INFO
Shared By:
Stats:
views:1
posted:6/26/2013
language:
pages:8
Description: The U.S. vaccine market is estimated to be worth USD 12.8 billion in 2012 and is further expected to reach USD 17.4 billion by 2018, growing at a CAGR of 5.3% from 2012 to 2018. Human vaccine segment occupies about 80% of the U.S. vaccine market. U.S. will continue to lead the global vaccine market due to rising prevalence of infectious diseases in humans and animals, and advancement in biotechnology in the region. Short functional shelf life of certain vaccines will have negative impact on the market growth, but huge product pipeline of the multinational firms will overcome this concern and will drive the future growth of the market. Browse Report : http://www.transparencymarketresearch.com/us-vaccine-market.html